(P-TS-50) Evaluating the Impact of Pathogen-Reduced Cryoprecipitated Fibrinogen Complex on Wastage and Operational Efficiency: A Three-Year Institutional Review

Background/Case Studies: Traditional Cryoprecipitate Anti-Hemophilic Factor (Cryo AHF) has a limited post-thaw shelf life of 4-6 hours, restricting thawed inventory and often resulting in product wastage in blood banks. Pathogen Reduced Cryoprecipitated Fibrinogen Complex (PRCFC/Intercept Cryoprecipitate, Cerus), manufactured using amotosalen/UVA treated plasma, offers a 5-day room temperature post-thaw shelf life. Our institution implemented PRCFC in January 2022. This study evaluates the impact of PRCFC on product wastage and operational efficiency in our transfusion service over a three-year period.

Study

Design/Methods: A retrospective review study was conducted of cryoprecipitate usage and wastage from 2022-2025. Utilization records were extracted for both Cryo AHF and PRCFC. Wastage was defined as thawed units that were discarded without patient use. Data were aggregated annually. Estimated cost implications were derived using institutional unit pricing and total wastage. Turnaround time (TAT) metrics from order to issue were also reviewed, though was not the primary outcome.

Results/Findings: From 2022-2025, a total of 6,159 Cryo AHF units and 2,163 PRCFC units (26% of our blood bank total cryoprecipitate inventory) were transfused. PRCFC was used in the operation room (OR) and labor and delivery (L & D) floor. A total of 271 Cryoprecipitate units were discarded (260 Cryo AHF, 11 PRCFC) since January 2022. Annual PRCFC wastage remained consistently < 1% despite increasing usage each year, with absolute reductions in wastage ranging from 3.9% - 4.3% compared to Cryo AHF (p < 0.001) (Table 1). A total amount of $103,166 Cryo AHF has been wasted, compared to $7,700 PRCFC, over three years in our blood bank.

There was a significant reduction in TAT from order to issue (7.4± 4.2 minutes Cryo PRCFC vs 28.1± 9.5 minutes Cryo AHF) by using PRCFC instead of Cryo AHF for orders placed from the OR and L&D (p < 0.001).

Conclusions: Implementation of PRCFC resulted in a statistically significant reduction in blood bank product wastage. Additionally, it demonstrated evidence of cost savings in our blood bank over three years, while maintaining rapid availability and quality in the blood bank.